Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
Atea Pharmaceuticals (Nasdaq: AVIR) presented new data at The Liver Meeting 2025 supporting its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) as a potential best-in-class, short-duration HCV regimen. Key findings include a modeled time to cure of ~7–8 weeks, Phase 2 SVR12 of 98% in the per-protocol population and 95% regardless of adherence, a resistance analysis showing a high barrier to resistance, and Phase 1 data showing the FDC has high relative bioavailability and can be dosed with or without food or with famotidine. The commercial FDC is being used in the ongoing Phase 3 program. A virtual KOL investor panel is scheduled for Nov 13, 2025 at 10:00 AM ET.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET to report third quarter results for the period ended September 30, 2025 and provide a business update.
Participants may register for the live call, access the audio webcast under Events and Presentations on Atea's Investor Relations site at ir.ateapharma.com, or join by telephone using the provided U.S. and international dial‑in numbers and conference ID 10203461. An archive of the webcast will be posted about two hours after the call and will remain available for at least 90 days.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a virtual hepatitis C (HCV) key opinion leader panel on November 13, 2025 at 10:00 AM ET.
The panel will cover the HCV patient population, early diagnosis and treatment, public policy including test-and-treat, prospects for HCV eradication in North America, and what an optimized HCV therapy could offer prescribers and patients. Company management will discuss the HCV commercial market opportunity and Atea’s global Phase 3 program evaluating a bemnifosbuvir plus ruzasvir regimen. A live Q&A will follow; registration is required.
Panelists include: Jordan Feld MD MPH, Eric Lawitz MD, Anthony Martinez MD, and Nancy Reau MD.
Atea Pharmaceuticals (Nasdaq: AVIR) will present new data at The Liver Meeting® 2025 (Nov 7-11, Washington, DC) supporting the combination regimen of bemnifosbuvir and ruzasvir for hepatitis C. Three accepted abstracts cover multiscale Phase 2 modeling, a viral resistance analysis, and a Phase 1 food-effect/bioavailability study for a fixed-dose combination. Prior Phase 2 results (n=275) showed SVR12 98% in the per-protocol treatment-adherent population and 95% in the efficacy-evaluable population. A virtual KOL investor event is scheduled for Nov 13, 2025 at 10:00 AM ET.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference.
The company's management team will engage in a fireside chat on September 9, 2025, at 1:05 p.m. ET in New York. Investors can access the presentation through a live webcast on the company's investor relations website, with the recording remaining available for at least 90 days after the event.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Q2 2025 financial results and provided updates on its HCV treatment program. The company's Phase 3 trials (C-BEYOND and C-FORWARD) are advancing for its bemnifosbuvir/ruzasvir combination therapy, with enrollment on track in both studies. The Phase 2 study showed promising results with a 98% sustained virologic response at 12 weeks post-treatment.
Financial highlights include cash position of $379.7 million as of June 30, 2025, compared to $454.7 million at end of 2024. The company reported a net loss of $37.2 million for Q2 2025. Atea has repurchased 4.6 million shares at an average price of $3.01 per share under its $25 million buyback program and is exploring strategic alternatives with Evercore.
The company presented four scientific posters at EASL 2025, demonstrating the potential best-in-class profile of its HCV regimen with advantages including short treatment duration, low drug-drug interaction risk, and no food effect requirements.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has scheduled its second quarter 2025 financial results and business update conference call for August 7, 2025, at 4:30 p.m. ET.
The company will host both a live conference call and audio webcast, with the webcast available under the "Events and Presentations" section of Atea's investor relations website. Participants can join via phone by dialing 1-877-300-8521 (U.S.) or 1-412-317-6026 (International) using conference ID 10201618.
Atea Pharmaceuticals (Nasdaq: AVIR) has announced the dosing of its first patient in the global Phase 3 C-FORWARD trial outside North America for its HCV treatment program. The trial evaluates the combination of bemnifosbuvir and ruzasvir against sofosbuvir and velpatasvir for hepatitis C virus treatment.
The treatment regimen is administered once-daily for 8 weeks in patients without cirrhosis or 12 weeks in patients with compensated cirrhosis. This marks the second Phase 3 trial in Atea's global program, following C-BEYOND which began enrolling patients in the US and Canada in April 2025.
The company aims to develop a best-in-class HCV regimen with potential advantages including shorter treatment duration, low risk for drug-drug interactions, and no food effect requirements. HCV remains a significant health burden, affecting approximately 50 million people globally, including up to 4 million in the US.